



Memo Therapeutics AG announces proof of concept of its *huMemoMAB*[™] antibody technology platform.

Basel/Zurich, Switzerland, May 23, 2017, Memo Therapeutics AG, a privately-held therapeutic antibody company today announced discovery of its first human antibodies using its proprietary *huMemoMAB*[™] antibody discovery platform.

A first series of human monoclonal antibodies against a viral antigen has been identified from a human donor-derived antibody repertoire (antibodyome) library using its *huMemoMAB*[™] antibody discovery platform.

MEMO's CSO Christoph Esslinger commented: "This result is a first step towards MEMO's vision to build and exploit cognate human antibodyome libraries from clinically selected donors. We will use this technology for discovery of antibodies with therapeutic potential in a broad range of disease areas."

"MEMO has now a best in class antibody discovery platform for discovery from human donors / patients, *huMemoMAB*[™], and immunized rabbits, *rbMemoMAB*[™], respectively. This puts MEMO in a unique position for any antibody discovery program" CEO Armin Mäder added.

This discovery project has been started through a Swiss Government sponsored CTI program of MEMO with leading Swiss Universities. It also involves 3 non-interventional clinical study protocols in which more than 70 patients and healthy donors have already been recruited for MEMO's future antibody repertoire library.

About MemoMAB[™]

MemoMAB[™] is a single cell-based technology platform and the only technology to date that enables banking and expression screening of large authentic antibody repertoires (antibodyomes) of human and animal origin. It uses state of the art high throughput single cell technology for the rapid/fast processing of millions of antibody producing cells.

huMemoMAB[™], the process for human B cells, opens up new opportunities in the fields of immune repertoire analysis, antibody- and target discovery:

- Rapid banking of complete authentic antibody repertoires of human or animal donors
- Unmatched repertoire analysis by single-cell based expression screening
- Unmatched efficiency resulting in more antibodies to choose from



About Memo Therapeutics AG:

Memo Therapeutics AG, a Spin Off of the Swiss Federal Institute of Technology (ETHZ) is an innovator in the field of antibody discovery and immune repertoire analysis. MEMO is a preclinical startup and focuses on proprietary lead generation programs and collaborations with the biotech/pharma industry.



Media contact:

media@memo-therapeutics.com

MEMO's technology platform:

[MemoMAB™ video](#)

www.memo-therapeutics.com

Memo Therapeutics AG, c/o BPL D-BSSE ETH, Mattenstrasse 26, 4058 Basel, Switzerland.